About AngioDynamics (NASDAQ:ANGO)
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. In addition, the company provides thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. Further, it offers peripherally inserted central catheters; ports that are implantable devices for the central venous administration; and dialysis products. Additionally, the company provides microwave ablation products; radiofrequency ablation products for ablating solid cancerous or benign tumors; and NanoKnife ablation systems for the surgical ablation of soft tissues. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, and interventional and surgical oncologists directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ANGO
CUSIP03475V10
Phone518-795-1400
Debt
Debt-to-Equity Ratio0.16%
Current Ratio2.88%
Quick Ratio1.84%
Price-To-Earnings
Trailing P/E Ratio27.64
Forward P/E Ratio26.66
P/E Growth1.79
Sales & Book Value
Annual Sales$349.64 million
Price / Sales2.08
Cash Flow$1.3973 per share
Price / Cash14.12
Book Value$14.63 per share
Price / Book1.35
Profitability
EPS (Most Recent Fiscal Year)$0.73
Net Income$5 million
Net Margins0.97%
Return on Equity5.11%
Return on Assets3.81%
Miscellaneous
Employees1,250
Outstanding Shares36,810,000
AngioDynamics (NASDAQ:ANGO) Frequently Asked Questions
What is AngioDynamics' stock symbol?
AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."
How were AngioDynamics' earnings last quarter?
AngioDynamics, Inc. (NASDAQ:ANGO) issued its quarterly earnings results on Thursday, March, 29th. The medical instruments supplier reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.05. The medical instruments supplier had revenue of $83.85 million for the quarter, compared to the consensus estimate of $86.13 million. AngioDynamics had a return on equity of 5.11% and a net margin of 0.97%. View AngioDynamics' Earnings History.
When is AngioDynamics' next earnings date?
What price target have analysts set for ANGO?
7 Wall Street analysts have issued 1-year price targets for AngioDynamics' stock. Their forecasts range from $16.00 to $21.00. On average, they anticipate AngioDynamics' stock price to reach $17.5825 in the next year. View Analyst Ratings for AngioDynamics.
Who are some of AngioDynamics' key competitors?
Some companies that are related to AngioDynamics include NuVasive (NUVA), Nevro (NVRO), Merit Medical Systems (MMSI), NovoCure (NVCR), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), OraSure Technologies (OSUR), Glaukos (GKOS), Luminex (LMNX), K2M Group (KTWO), MiMedx Group (MDXG) and CryoLife (CRY).
Who are AngioDynamics' key executives?
AngioDynamics' management team includes the folowing people:
- Mr. James C. Clemmer, Pres, CEO & Director (Age 54)
- Mr. Michael C. Greiner, Exec. VP, CFO & Principal Accounting Officer (Age 45)
- Mr. Stephen A. Trowbridge, Sr. VP, Gen. Counsel & Assistant Sec. (Age 44)
- Mr. Chad T. Campbell, Sr. VP Global Vascular Access (Age 47)
- Mr. Robert A. Simpson, Sr. VP Peripheral Vascular (Age 46)
Has AngioDynamics been receiving favorable news coverage?
Headlines about ANGO stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AngioDynamics earned a news sentiment score of 0.13 on Accern's scale. They also assigned news articles about the medical instruments supplier an impact score of 47.19 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of AngioDynamics?
Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AngioDynamics' stock price today?
One share of ANGO stock can currently be purchased for approximately $19.73.
How big of a company is AngioDynamics?
AngioDynamics has a market capitalization of $732.41 million and generates $349.64 million in revenue each year. The medical instruments supplier earns $5 million in net income (profit) each year or $0.73 on an earnings per share basis. AngioDynamics employs 1,250 workers across the globe.
How can I contact AngioDynamics?
AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]
MarketBeat Community Rating for AngioDynamics (ANGO)
MarketBeat's community ratings are surveys of what our community members think about AngioDynamics and other stocks. Vote "Outperform" if you believe ANGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
AngioDynamics (NASDAQ:ANGO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for AngioDynamics in the last 12 months. Their average twelve-month price target is $17.5825, suggesting that the stock has a possible downside of 10.88%. The high price target for ANGO is $21.00 and the low price target for ANGO is $16.00. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.43 | 2.20 | 2.20 | 2.40 |
| Ratings Breakdown: | 0 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $17.5825 | $18.50 | $18.50 | $18.50 |
| Price Target Upside: | 10.88% downside | 17.76% upside | 17.76% upside | 8.63% upside |
AngioDynamics (NASDAQ:ANGO) Consensus Price Target History
AngioDynamics (NASDAQ:ANGO) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
AngioDynamics (NASDAQ:ANGO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
AngioDynamics (NASDAQ ANGO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.80%
Institutional Ownership Percentage: 95.43%
AngioDynamics (NASDAQ ANGO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 7/24/2017 | Jan Stern Reed | Director | Buy | 316 | $16.00 | $5,056.00 | 316 |  |
| 7/21/2017 | James C Clemmer | CEO | Buy | 5,000 | $15.79 | $78,950.00 | 86,683 | |
| 7/20/2017 | James C Clemmer | CEO | Buy | 20,000 | $15.64 | $312,800.00 | 86,683 | |
| 4/12/2017 | Avista Capital Partners Gp, Ll | Major Shareholder | Sell | 2,350,000 | $16.00 | $37,600,000.00 | | |
| 8/5/2016 | Avista Capital Partners Gp, Ll | Major Shareholder | Sell | 2,241,000 | $14.62 | $32,763,420.00 | | |
| 8/5/2016 | David F Burgstahler | Director | Sell | 2,250,000 | $14.62 | $32,895,000.00 | 23,988 | |
| 5/6/2016 | Charles R Greiner | VP | Sell | 3,508 | $12.31 | $43,183.48 | 20,910 | |
| 4/25/2016 | Stephen A Trowbridge | SVP | Sell | 12,940 | $12.30 | $159,162.00 | 32,469 | |
| 4/14/2014 | Matthew Kapusta | SVP | Buy | 1,000 | $13.90 | $13,900.00 | 27,005 | |
| 10/18/2013 | Vincent Bucci | Director | Buy | 5,000 | $15.20 | $76,000.00 | | |
| 10/17/2013 | Howard W Donnelly | Director | Sell | 20,000 | $15.06 | $301,200.00 | | |
| 7/22/2013 | Kevin J Gould | Director | Buy | 2,700 | $12.00 | $32,400.00 | | |
| 5/9/2013 | Charles R Greiner | VP | Sell | 1,495 | $10.38 | $15,518.10 | | |
| 3/12/2013 | Vincent Bucci | Director | Buy | 85,000 | $10.77 | $915,450.00 | | |
| 2/14/2013 | Vincent Bucci | Director | Buy | 2,000 | $12.17 | $24,340.00 | | |
| 1/11/2013 | Kevin J Gould | Director | Buy | 2,700 | $11.58 | $31,266.00 | | |
| 11/5/2012 | Jeffrey Gold | Director | Buy | 1,000 | $10.56 | $10,560.00 | | |
(Data available from 1/1/2013 forward)
AngioDynamics (NASDAQ ANGO) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | AngioDynamics (ANGO) & Its Peers Head to Head Comparison
www.americanbankingnews.com - April 24 at 11:02 PM |
 | Global Varicose Vein Treatment Market Overview 2017-2026: Sciton Inc, Energist Ltd, AngioDynamics Inc
www.marketwatch.com - April 24 at 9:16 AM |
| AngioDynamics (ANGO) Price Target Increased to $21.00 by Analysts at Cantor Fitzgerald
www.americanbankingnews.com - April 19 at 11:52 PM |
| AngioDynamics, Inc. (ANGO) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 19 at 5:40 PM |
| AngioDynamics (ANGO) Upgraded to B- by TheStreet
www.americanbankingnews.com - April 18 at 10:41 AM |
| AngioDynamics (ANGO) Downgraded by BidaskClub
www.americanbankingnews.com - April 14 at 6:23 PM |
| $88.99 Million in Sales Expected for AngioDynamics, Inc. (ANGO) This Quarter
www.americanbankingnews.com - April 11 at 2:40 AM |
 | AngioDynamics to Present at Two Investor Conferences in May
finance.yahoo.com - April 10 at 4:36 PM |
| AngioDynamics (ANGO) Raised to Strong-Buy at BidaskClub
www.americanbankingnews.com - April 10 at 11:28 AM |
| Zacks: Brokerages Expect AngioDynamics, Inc. (ANGO) to Announce $0.21 EPS
www.americanbankingnews.com - April 9 at 3:21 PM |
| AngioDynamics (ANGO) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - April 8 at 10:49 AM |
| AngioDynamics (ANGO) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 6 at 11:38 AM |
| Blog Exposure - Waters Corp. to Significantly Expand its Precision Chemistry Facility in Massachusetts
finance.yahoo.com - April 5 at 4:33 PM |
| AngioDynamics (ANGO) Product Line Strong, Debt Level High
finance.yahoo.com - April 3 at 4:37 PM |
| Raymond James Financial Upgrades AngioDynamics (ANGO) to Outperform
www.americanbankingnews.com - April 3 at 10:43 AM |
| AngioDynamics (ANGO) Upgraded at UBS
www.americanbankingnews.com - April 3 at 7:48 AM |
| AngioDynamics (ANGO) PT Raised to $17.00 at Canaccord Genuity
www.americanbankingnews.com - April 2 at 2:38 PM |
 | AngioDynamics (ANGO) Beats on Q3 Earnings, Reiterates View
www.zacks.com - April 2 at 9:47 AM |
| AngioDynamics (ANGO) Q3 2018 Earnings Conference Call Transcript
finance.yahoo.com - April 1 at 4:59 PM |
| AngioDynamics (ANGO) Downgraded by TheStreet to C
www.americanbankingnews.com - March 30 at 5:08 PM |
| AngioDynamics (ANGO) Raised to Buy at BidaskClub
www.americanbankingnews.com - March 30 at 1:06 PM |
| Edited Transcript of ANGO earnings conference call or presentation 29-Mar-18 12:00pm GMT
finance.yahoo.com - March 30 at 9:24 AM |
| AngioDynamics (ANGO) Posts Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - March 30 at 7:52 AM |
| Head to Head Survey: AngioDynamics (ANGO) vs. Its Peers
www.americanbankingnews.com - March 30 at 3:06 AM |
 | AngioDynamics beats by $0.06, misses on revenue
seekingalpha.com - March 29 at 4:35 PM |
| AngioDynamics Q3 revenues down 2%; non-GAAP EPS up 32%
seekingalpha.com - March 29 at 9:41 AM |
| AngioDynamics misses 3Q revenue forecasts
finance.yahoo.com - March 29 at 9:41 AM |
| Where AngioDynamics Inc (NASDAQ:ANGO) Stands In Earnings Growth Against Its Industry
finance.yahoo.com - March 29 at 9:41 AM |
| AngioDynamics (ANGO) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 28 at 4:33 PM |
| AngioDynamics, Inc. (ANGO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 25 at 5:18 PM |
| AngioDynamics (ANGO) Lifted to "Hold" at BidaskClub
www.americanbankingnews.com - March 25 at 3:47 PM |
| AngioDynamics, Inc. (ANGO) Expected to Announce Earnings of $0.20 Per Share
www.americanbankingnews.com - March 23 at 3:17 PM |
| Global Vascular Access Devices Market Opportunities 2018: R. Bard, Braun Melsungen AG, Dickinson and Company, AngioDynamics
www.marketwatch.com - March 21 at 10:26 AM |
| AngioDynamics (ANGO) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - March 21 at 1:36 AM |
| AngioDynamics to Present at the Needham 17th Annual Healthcare Conference
finance.yahoo.com - March 15 at 5:04 PM |
| AngioDynamics, Inc. (ANGO) Expected to Announce Quarterly Sales of $86.13 Million
www.americanbankingnews.com - March 8 at 7:54 AM |
| $0.20 Earnings Per Share Expected for AngioDynamics, Inc. (ANGO) This Quarter
www.americanbankingnews.com - March 6 at 9:42 AM |
| Arrowstreet Capital Limited Partnership Purchases 29,400 Shares of AngioDynamics, Inc. (ANGO)
www.americanbankingnews.com - March 6 at 4:35 AM |
| Broadfin Capital LLC Has $28.81 Million Position in AngioDynamics, Inc. (ANGO)
www.americanbankingnews.com - March 2 at 5:08 AM |
| Spark Investment Management LLC Raises Stake in AngioDynamics, Inc. (ANGO)
www.americanbankingnews.com - March 1 at 6:58 PM |
| AngioDynamics, Inc. (ANGO) Shares Sold by Martingale Asset Management L P
www.americanbankingnews.com - March 1 at 9:34 AM |
| A Look at the Performances of Abaxis’s Product Categories
finance.yahoo.com - March 1 at 9:04 AM |
| Analysts’ Ratings for Abaxis and Its Peers in February 2018
finance.yahoo.com - March 1 at 9:04 AM |
| AngioDynamics, Inc. (ANGO) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 28 at 7:42 PM |
| Citadel Advisors LLC Has $2 Million Holdings in AngioDynamics, Inc. (ANGO)
www.americanbankingnews.com - February 28 at 10:52 AM |
| AngioDynamics to Report Fiscal 2018 Third Quarter Financial Results on March 29, 2018
finance.yahoo.com - February 27 at 5:09 PM |
| AngioDynamics, Inc. (ANGO) Shares Bought by Pinebridge Investments L.P.
www.americanbankingnews.com - February 26 at 11:52 AM |
| AngioDynamics (ANGO) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - February 25 at 6:03 PM |
| $86.13 Million in Sales Expected for AngioDynamics, Inc. (ANGO) This Quarter
www.americanbankingnews.com - February 19 at 3:52 AM |
| BidaskClub Downgrades AngioDynamics (ANGO) to Sell
www.americanbankingnews.com - February 17 at 11:36 PM |
AngioDynamics (NASDAQ:ANGO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
AngioDynamics (NASDAQ:ANGO) Income Statement, Balance Sheet and Cash Flow Statement
AngioDynamics (NASDAQ ANGO) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
